Aim: Second primary tumor (SPT) is a serious late complication after definitive radiotherapy for nasopharyngeal carcinoma (NPC). We evaluated the incidence, pattern, risk factors and survival impact of SPT in NPC patients following definitive intensity-modulated radiotherapy (IMRT).
BACKGROUND
Intensity-modulated radiotherapy (IMRT) has replaced conventional two-dimensional radiotherapy (2D RT) as the standard definitive treatment for nonmetastatic nasopharyngeal carcinoma (NPC) for more than a decade. This technical advancement has improved disease control alongside with a reduction in radiotherapy late toxicities. 1, 2 Although IMRT enables highly conformal tumor coverage thereby avoids excessive radiation to several critical structures, a large volume of normal tissue is exposed to a "low-dose radiation bath" due to its multiple-beam arrangement. The need for longer beam-on time also increases whole body integral dose from head leakage and collimator scatter. 3 These have led to concerns on an increased risk of radiationinduced second primary tumor (SPT) with this technique. 4, 5 SPT is one of the most dreadful complications for survivors of head and neck cancers, accounting for 23% of deaths in patients with nonmetastatic diseases who survived at least 3 years after diagnosis. 6 Incidences of SPT in NPC patients treated with definitive 2D RT have been reported in multiple series, quoting rates of 0.6-5.6% over variable follow-up periods. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] However, data from cohorts treated with IMRT is scarce and of limited follow-up duration. 17 As radiation-associated tumors often develop after years or even decades of latency, the actual incidences and tumor patterns might be underrepresented if follow-up time is short. In addition, it is more informative when the observed incidences are quantified with reference to background population risk.
This study attempted to examine the risk of SPT in a large uniform cohort of IMRT-treated NPC patients, determine factors associated with SPT development, assess its impact on patients' survival and to check for excess cancer risks with comparisons made with registrybased incidence data of the general population. 18 Selected stage II, and all stage III to IV patients with good performance status and renal function were treated with concurrent chemoirradiation using cisplatin 100 mg/m 2 every 3 weeks or 30 mg/m 2 weekly. Neo-adjuvant or adjuvant chemotherapy regimens were used in advanced diseases, most commonly being cisplatin in combinations with either gemcitabine or 5-fluorouracil.
METHODS

Study population
Initial definitive treatments
Follow-up
Follow-up duration was calculated from date of radiotherapy completion to last clinical visit. Patients were followed up every 3-6 months in first 3 years and then every 6-12 months thereafter. Diagnosis of SPT followed the criteria of Warren and Gates, 19 modified by Morris et al. 20 Patients with history of prior malignancy, third primary tumors or SPTs diagnosed in less than 6-month interval from completion of radiotherapy were excluded. SPTs were considered as in-field if their epicenters lied within previous radiotherapy fields, which included hematological malignancies. All SPTs were pathologically confirmed, except for hepatocellular carcinomas which were diagnosed by raised alphafetoprotein levels and typical radiological features.
Statistical analysis
Descriptive statistical analysis were used for patient demographics and clinico-pathologic characteristics. The Kaplan-Meier method was used to estimate cumulative incidence of SPT and overall survival after SPT diagnosis. Univariate analysis of the relationship between clinical characteristics and risk of SPT development was performed using the log-rank test. The Cox proportional hazards model was used in multivariate analyses, using a backward stepwise selection method including variables with P-value < 0.1. Variables examined included age, sex, smoking status, stage of NPC, exposure to chemotherapy and history of re-irradiation.
To compare SPT incidences in our cohort with the general population, cancer incidence rates were obtained from the Hong Kong Cancer Registry, stratified by 5-year age, gender and calendar-year. The incidence rates were multiplied by person-years at risk to obtain the expected number of SPT for each cancer type. Standardized incidence ratios (SIR), defined by the ratios between expected and observed number, were then calculated. Ninety-five percent confidence intervals (CI) were determined using Byar's approximation, based on the assumption that the data followed a Poisson distribution.
All analyses were performed using SPSS Statistics, version 22.0 (SPSS Inc. Chicago, IL, USA). All tests were two-sided, statistical significance was set at the cut-off of P < 0.05.
RESULTS
Patient characteristics
There were 780 patients treated with definitive IMRT during study period, 21 of which had history of malignancy before diagnosis of NPC and were excluded from analysis. Table 1 
TA B L E 1 Patient demographics and treatment characteristics
TA B L E 2 Univariate and multivariate analyses of factors associated with second primary tumor development
All SPTs (n = 51) In-field SPTs (n = 22) Out-field SPTs (n = 29)
Univariate analysis (log-rank) Abbreviations: CI, confidence interval; SIR, standardized incidence ratio; SPT, second primary tumor.
Factors associated with SPT development
Results of univariate and multivariate analyses are shown in Table 2 .
Both advanced age [hazard ratio (HR), 1.051; 95% confidence interval (CI), 1.025-1.078] and smoking (HR, 1.755; 95% CI, 1.002-3.075) were independent predictive risk factors for SPT development. Similar associations were observed in the out-field SPT subgroup. For SPTs occurring within previous IMRT fields, no independent risk factor was identified. However, a history of re-irradiation showed a trend for higher risk of SPT development (HR, 4.000; 95% CI, 0.922-17.346).
Excess cancer risks
We compared the observed numbers of SPTs with those expected if our cohort came from the general Hong Kong population. SIRs derived from age, gender and calendar-year specific cancer incidences were shown in Table 3 . The total number of SPTs observed (n = 51) was significantly higher than the expected number of 27. cancer types with elevated SIRs at statistical significance were further stratified by follow-up intervals using 5 years as cut-off. Consistently, higher excess risks were observed at follow-up beyond 5 years (Table 4) . Abbreviations: CI, confidence interval; n/a, not applicable; SIR, standardized incidence ratio; SPT, second primary tumor. a Included the 4 second cancers diagnosed within 6 months of IMRT completion.
TA B L E 4
Standardized incidence ratios of second primary tumors by follow-up time SPT Type Follow-up time Expected number Observed number
DISCUSSION
Nasopharyngeal carcinoma is a radiosensitive tumor, excellent disease control can be achieved after definitive chemo-irradiation using IMRT technique. With more long-term survivors, the detrimental impact of late complications such as second malignancies also correspondingly increases. Almost all of the current existing data on post-radiotherapy SPT incidence in NPC came from the 2D RT era, quoting estimates of 0.6-5.6% across variable follow-up durations. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Very few studies evaluated this risk in a uniform cohort of IMRT-treated patients.
In this study of 780 NPC patients who underwent definitive treatments using contemporary IMRT, we identified an overall SPT incidence of 6.7%. Although this numerically higher incidence may have reflected our long follow-up duration, the point estimates of in-field SPT risks at 3 years (0.4%) and 5 years (1.5%) were similar to the 0.35% and 1.2% reported by Kong et al. in the 2D RT era a decade ago. 12 More importantly, as patients' recurrence risk reduces with longer periods of disease remission, an upward trend of in-field SPT incidence was observed, reaching an estimate of 3.0% at 8 years. This nonlinear incidence pattern may be attributable to a combined effect of aging and the late carcinogenic property of radiation exposure. 12, 14 we identified age as an independent risk factor for SPT development, estimating an 81% risk increment for every 10 years of age. This pattern follows those of most primary malignancies, of which incidences and age are often positively correlated. Another associating risk factor, tobacco smoking, is a strong established carcinogen for numerous cancer types, and was at the same time confirmed to promote EBV activation hence viral carcinogenesis in NPC. 21 This phenomenon of shared environmental risk factor potentially explains the large proportion of SPTs in lung and upper aero-digestive tract in the current NPC cohort, where such observation was previously reported in nonnasopharyngeal head and neck cancers as well. 22 In this study, a very strong excess risk of second tongue cancers was observed, accounting for approximately one-third of all in-field SPTs.
Corroborated with findings from Tsou et al. and Kong et al,
Our finding was consistent with that from Teo et al., who reported seven (0.8%) cases of second tongue cancers in 903 NPC patients treated with 2D RT, most of which were found near the bases of tongue. 25 Interestingly, although a comparable second tongue cancer incidence of 0.9% was noted in our IMRT cohort, we observed a distinctly different pattern of tumor location. Among the seven tongue cancers identified, six were found at lateral edges of mid-tongue, with only one situated at the base of tongue. Such a pattern change may be attributable to the difference in oral cavity dose distribution between the two radiotherapy techniques. In 2D RT, which traditionally employs a pair opposing facio-cervical fields, the tongue base would typically fall into zones of high-dose radiation. In contrast, with the use of multiple beam arrangements and the consistent inclusion of level Ib nodal group as treatment targets, IMRT produces plans with wider spread of low-dose volumes covering the anterior and lateral edges of tongue. 26 This change in locations of second tongue cancers along with the transition of radiotherapy techniques carries potential clinical implications, as oral tongue cancers tend to present early and are often more surgically treatable than primaries arising from base of tongue.
Another third of in-field SPTs in our series were post-irradiation head and neck sarcomas. In contrary to most other second cancers, post-irradiation sarcomas typically develop at heavily irradiated regions, and there were evidences supporting a dose-dependent incidence pattern. 27 By replacing 2D RT with IMRT, there is increased tissue exposure to low-dose radiation, in exchange for a reduction in high-dose volume from improved target conformity. Therefore, it was previously postulated that the risk of second sarcomas may drop with widespread use of IMRT. 28 In the 2D RT era, the crude incidence of in-field sarcomas was 0.14-0.35% across different series. [29] [30] [31] In this study, the estimated crude incidence of in-field sarcomas was 0.9%.
Although direct comparisons with historical data is difficult due to great variations in follow-up durations and latency criteria, our finding does not support previous speculation for a risk reduction in second sarcomas with IMRT. Because post-irradiation sarcomas are known to develop at very long latency periods, together with current improvement of survival with IMRT, further observation with long term followup is required to fully reveal its actual risk.
The present series reported an 84% excess cancer risk in IMRTtreated NPC survivors compared with the general population. Our estimate agrees with a hospital-based study in the era of 2D RT, which reported an overall SIR of 1.93 and identified substantially elevated numbers of tongue, brain, nasal and middle ear cancers. 11 In concordance, we quantified a highly significant excess risk of tongue cancer (SIR, 33.33; 95% CI, 13.36-68.67), at a magnitude greater than the previously reported SIR of 25.7. However, in our cohort, no excess risk for second brain, nasal or middle ear cancers were observed. This discrepancy in SPT patterns potentially reflects the difference in radiotherapy field arrangements between 2D RT and IMRT. In conventional 2D
RT for NPC, the middle ears typically lied within the parallel opposed fields, and a second-phase anterior facial field was often in place, which was at direct incidence to the whole nasal cavity. IMRT, however, could effectively spare auditory apparatuses from high dose radiation, and To our knowledge, this study was the largest published series to date in assessment of SPT risk in IMRT-treated NPC. This study had the strengths of a long follow-up duration, and a high certainty on the diagnoses of SPTs as all data were verified with individual patient records.
However, our work holds several limitations. First, in the absence of smoking-status specific cancer incidence data of the general population, our current estimates of excess cancer risks are likely a reflection of both the resultant effect of radiation exposure and differences in smoking pattern. The proportion of ever-smoker in our cohort was 43%, higher than the corresponding age-and sex-adjusted smoking prevalence of 22% in background Hong Kong population. Therefore, although the elevated sarcoma risk is chiefly attributable to radiation exposure, the excess risk noted for other cancers of the upper aerodigestive tract (including tongue cancer) is best interpreted as a mixed carcinogenic effect of smoking and radiation. Also, as limited by the retrospective nature of our study, other determinants of cancer such as details in smoking pack-years and alcohol consumption were not available. The dichotomization of smoking status may also have diluted its effect as an independent risk factor for SPT development. Moreover, although the Hong Kong Cancer Registry reaches a high benchmark of data completeness with more than 85% of diagnoses being pathologically verified, 34 comparisons made between hospital-based data with a population-based registry may still result in errors in SIR estimations due to their differences in case-capturing method. In addition, some of the observed SPTs were of small numbers, hence might have given rise to chance association in SIR calculations. Also, without direct comparison made between radiotherapy plans from 2D RT and IMRT, the observed differences in SPT patterns between our study and the published data remained hypothesis-generating. However, our findings can serve to provide foundation for future registry-based work to better illustrate the change in second cancer patterns along with this technical advancement.
CONCLUSIONS
In conclusion, our study confirmed SPT as a major health problem for NPC survivors after definitive IMRT. Very high excess risks of developing in-field sarcomas and second tongue cancers were identified, particularly after a latency period of more than 5 years. A change in SPT pattern was observed, potentially attributable to the dosimetric differences between radiotherapy techniques. Clinicians should maintain a high level of vigilance, and consider employing routine surveillance for this dreadful late complication in NPC survivors.
